Researchers published findings in Nature Communications mapping recurring and novel evolutionary routes by which HIV‑1 acquires resistance to lenacapavir, a long‑acting capsid inhibitor. The work enumerates mutations and compensatory changes that reduce drug binding and outlines cross‑resistance risks with emerging antiretroviral regimens. The authors emphasize that surveillance of resistance patterns and incorporation of these pathways into diagnostic panels will be critical as lenacapavir deployment expands.